A delta-based multi-omics model to predict adaptive radiotherapy benefit in patients with non-small cell lung cancer during carbon-ion radiotherapy

Key Points

• The aim is to develop a delta-omic model to predict the demand for adaptive radiotherapy (ART) in patients with non-small cell lung cancer (NSCLC) undergoing carbon-ion radiotherapy (CIRT).
• Developed a delta-omic model
• Assessed ART demand in NSCLC patients
• Highlighted the need for prospective validation in larger cohorts
• The delta-omic model may optimize resource allocation for ART workflows.
• Prospective validation is needed for wider clinical application.